Marc Veale has more than 25 years of finance and accounting experience in the life science industry and has held roles of increasing responsibility in companies that span from development stage biotechnology start-ups to large, publicly held global commercial pharmaceutical companies. Prior to joining Primmune in 2021, Marc was the corporate controller for GW Pharmaceuticals plc, where he played a key role in the buildout of U.S. operations and commercial readiness before it was acquired by Jazz Pharmaceuticals. Prior to GW, Marc held several senior level finance positions at Allergan from 2004 to 2016, most recently serving as vice president of finance transformation where he was responsible for key post-merger integration projects after Allergan’s acquisition by Actavis plc. While at Allergan, he also served as vice president, assistant corporate controller and was responsible for the implementation the Sarbanes-Oxley section 404 internal controls process. Marc began his career at Deloitte, where he was an audit manager. Marc holds a B.A. in Accounting and Business Administration from Point Loma Nazarene University and is a Certified Public Accountant.
Marc Veale
